Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene therapy aims to turn back the clock on aging

NCT ID NCT07285629

Disease control Sponsor: Minicircle Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This early-phase study is testing a gene therapy that delivers two proteins, klotho and follistatin, via a simple injection. The goal is to see if it is safe and can improve cognition and overall health in healthy adults aged 50 to 80. Thirty volunteers will receive the therapy and be monitored for side effects and changes in protein levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
klotho and follistatin gene therapy (nonviral plasmid injection)
What this could lead to
If successful, this could point toward a way to slow aging or improve cognitive function in older adults.
What could go wrong
This is a very early, small pilot study in only 30 healthy people. It is not yet tested for effectiveness, and side effects are unknown. Results may not apply to the general population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

14 people

The number who actually took part.

Started

Dec 2025

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 50 to 80 years * General good health * Willing to comply with all study-related procedures and visits * Participant is open to morphological change * If female, participant agrees to maintain contraception * If female, participant agrees to take a pregnancy test * If female, participant agrees to a pregnancy waiver Exclusion Criteria: * Currently enrolled in another clinical trial * History of cancer, autoimmune disease, or chronic kidney/liver disease * Use of immunosuppressive therapy * Pregnant or breastfeeding * Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study. * Regular use of NMDA (N-methyl-D-aspartate) antagonists (i.e., memantine, ketamine, etc.) * Regular use of antiplatelet medications (i.e., aspirin) * Any medical or psychiatric condition that could interfere with participation or pose safety concerns * Unwilling or unable to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy adults are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy adults

Contacts and locations

Locations

  • Apeiron Center

    Austin, Texas, 78701, United States

  • Global Alliance of Regenerative Medicine (GARM) Clinic

    Roatán, Bay Islands, Honduras

More trials for these conditions

Other studies related to the condition(s) this trial covers.